Journal of General Internal Medicine

, Volume 19, Issue 4, pp 380–389 | Cite as

Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease

  • Paul G. ShekelleEmail author
  • Sally C. Morton
  • Lara K. Jungvig
  • Jay Udani
  • Myles Spar
  • Wenli Tu
  • Marika J. Suttorp
  • Ian Coulter
  • Sydne J. Newberry
  • Mary Hardy


OBJECTIVE: To evaluate and synthesize the evidence on the effect of supplements of vitamin E on the prevention and treatment of cardiovascular disease.

DESIGN: Systematic review of placebo-controlled randomized controlled trials; meta-analysis where justified.

MEASUREMENTS AND MAIN RESULTS: Eighty-four eligible trials were identified. For the outcomes of all-cause mortality, cardiovascular mortality, fatal or nonfatal myocardial infarction, and blood lipids, neither supplements of vitamin E alone nor vitamin E given with other agents yielded a statistically significant beneficial or adverse pooled relative risk (for example, pooled relative risk of vitamin E alone=0.96 [95% confidence interval (CI), 0.84 to 1.10]; 0.97 [95% CI, 0.80 to 1.90]; and 0.72 [95% CI, 0.51 to 1.02] for all-cause mortality, cardiovascular mortality, and nonfatal myocardial infarction, respectively.

CONCLUSIONS: There is good evidence that vitamin E supplementation does not beneficially or adversely affect cardiovascular outcomes.

Key words

vitamin E antioxidants meta-analysis systematic review cardiovascular disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002.Google Scholar
  2. 2.
    Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I. General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.PubMedGoogle Scholar
  3. 3.
    Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med. 1995;123:860–72.PubMedGoogle Scholar
  4. 4.
    Diplock AT. Antioxidant nutrients and disease prevention. Am J Clin Nutr. 1991;53:S189-S93.Google Scholar
  5. 5.
    Hennekens CH, Gaziano JM. Antioxidants and heart disease: epidemiology and clinical evidence. Clin Cardiol. 1993;16(4 suppl):I10-I15.PubMedCrossRefGoogle Scholar
  6. 6.
    Maxwell S. Antioxidant vitamin supplements. Update of their potential benefits and possible risks. Drug Safety. 1999;21:253–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Clifton PM. Antioxidant vitamins and coronary heart disease risk. Curr Opin Lipidol. 1995;6:20–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med. 2002;251:372–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Tribble DL. Antioxidant consumption and risk of coronary heart disease. Emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;99:591–5.PubMedGoogle Scholar
  10. 10.
    Shekelle P, Morton S, Hardy M. Effect of Supplemental Antioxidants Vitamin C, Vitamin E, and Coenzyme Q10 for the Prevention and Treatment of Cardiovascular Disease. Evidence Report/Technology Assessment no. 83 (Prepared by Southern California RAND Evidence-Based Practice Center, under contract no. 290-97-0001). AHRQ Publication no. 03-E043. Rockville, Md: Agency for Health-care Research and Quality; 2003.Google Scholar
  11. 11.
    McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of the grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356:1228–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–13.PubMedCrossRefGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, Calif: Academic Press; 1985.Google Scholar
  17. 17.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRefGoogle Scholar
  18. 18.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRefGoogle Scholar
  19. 19.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedGoogle Scholar
  20. 20.
    Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20:230–5.PubMedGoogle Scholar
  21. 21.
    de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group Primary Prevention Project. Lancet. 2001;357:89–95.Google Scholar
  22. 22.
    Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Int Med. 2000;248:377–86.CrossRefGoogle Scholar
  23. 23.
    Mark SD, Wang W, Fraumeni JF, et al. Do nutritional supplements lower the risk of stroke or hypertension? Epidemiology. 1998;9:9–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.PubMedGoogle Scholar
  26. 26.
    Haeger K. The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol). Vasc Dis. 1968;5:199–213.PubMedGoogle Scholar
  27. 27.
    Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–60.PubMedCrossRefGoogle Scholar
  28. 28.
    GISSI-Prevenzione Investigators. (Gruppo Italiano per lo Studio della Sopravvianza nell’Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.Google Scholar
  29. 29.
    Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715–20.PubMedCrossRefGoogle Scholar
  30. 30.
    MRC/BHF Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.Google Scholar
  31. 31.
    Haeger K. Letter: vitamin E in intermittent claudication. Lancet. 1974;1:1352.PubMedCrossRefGoogle Scholar
  32. 32.
    Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J. 1977;93:444–9.PubMedGoogle Scholar
  33. 33.
    Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins Probucol Study Group. N Engl J Med. 1997;337:365–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart. 1998;79:454–8.PubMedGoogle Scholar
  36. 36.
    Brown BG, Xue-Qiao Z, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Ness A, Smith GD. Mortality in the CHAOS trial. Cambridge Heart Antioxidant Study. Lancet. 1999;353:1017–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol. 1996;77:232–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg. 1995;59:1519–23.PubMedCrossRefGoogle Scholar
  41. 41.
    Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347–53.PubMedCrossRefGoogle Scholar
  42. 42.
    Kaikkonen J, Kosonen L, Nyyssonen K, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercised-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic Res. 1998;13:1528–33.Google Scholar
  43. 43.
    Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol. 1997;44:94–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Porkkala-Sarataho E, Salonen JT, Nyyssonen K, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol. 2000;20:2087–93.PubMedGoogle Scholar
  45. 45.
    Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000;28:1100–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Iino K, Abe K, Kariya S, Kimura H, Kusaba T. A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. Jpn Heart J. 1977;18:277–83.PubMedGoogle Scholar
  47. 47.
    Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res. 2000;33:329–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Vivekananthan DP. Use of antioxidant vitamins for the prevention of cardiovascular disease. Lancet. 2003;361:2017–23.PubMedCrossRefGoogle Scholar
  49. 49.
    Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease. A summary of the evidence for the U.S. Preventive Services Task Force. Ann Int Med. 2003;139:56–70.PubMedGoogle Scholar
  50. 50.
    Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054–60.PubMedCrossRefGoogle Scholar
  51. 51.
    Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287:2973–82.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2004

Authors and Affiliations

  • Paul G. Shekelle
    • 1
    • 5
    Email author
  • Sally C. Morton
    • 1
  • Lara K. Jungvig
    • 1
  • Jay Udani
    • 2
    • 3
  • Myles Spar
    • 4
  • Wenli Tu
    • 1
  • Marika J. Suttorp
    • 1
  • Ian Coulter
    • 1
  • Sydne J. Newberry
    • 1
  • Mary Hardy
    • 1
    • 6
  1. 1.the Southern California Evidence-Based Practice CenterRand CorporationSanta Monica
  2. 2.Northridge Hospital Integrative Medicine ProgramLos Angeles
  3. 3.UCLA/Geffen School of MedicineLos Angeles
  4. 4.UCLA School of MedicineLos Angeles
  5. 5.Greater Los Angeles VA Healthcare SystemLos Angeles
  6. 6.Cedars-Sinai Medical CenterLos Angeles

Personalised recommendations